Weight-loss drug firm accused of prioritising profits after halting insulin pen production

Lecritia Roberts, a South African type 1 diabetes patient, expressed frustration, stating: "It feels as if the clock has been turned back on treatment. It makes me angry."

Campaigners have voiced that Novo Nordisk prioritizes profits by scaling up production of weight-loss injections at the expense of essential human insulin supplies, particularly affecting patients in developing countries.

Novo Nordisk has announced a $4bn investment in a US production plant to increase capabilities for injectable treatments for obesity, raising concerns over prioritization.

Roberts highlighted the disadvantages of using glass vials, recalling, "It was difficult to accurately administer, often embarrassing in public, and dropping the bottles could result in losing a month's worth of medicine."

Read at www.theguardian.com